🔗 Share this article

While America proceeds with sweeping changes to its immunization recommendations, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on coronavirus vaccines during the pandemic and has zeroed in on potential deaths after COVID-19 vaccination in her short position at the Food and Drug Administration.

Proposed Overhauls to Childhood Vaccine Program

Public health authorities had intended to reveal major changes to the childhood immunization program earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would put the US out of step with a large portion of the global community with no evidence for public health gain. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to speak at the gathering. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

Consolidating Power at the FDA

Høeg's temporary position might represent a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a renewed priority upon dismantling previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting certain childhood immunization guidelines in the US so as to align more like the Danish model, a society with comprehensive healthcare and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has persisted in emphasizing on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – as opposed to medication approval.

Questions Over Expertise

Dr. Høeg has no apparent background in medication creation, oversight or leadership, which has been customary for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a top consultant to the agency head and CBER since spring.

“It seems she lacks to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a large organization. She lacks background in pharmaceutical oversight.”

Previous heads of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Clearly, she doesn’t have the kind of background that prior appointees who headed the center have had.”

The drug center has an vast workload at the agency, the former commissioner stated.

“Everybody just focuses on the innovative therapies, but the generic program approves thousands of generic drugs. There’s a biologic copycat branch, over-the-counter program and so forth, and each of these need to be managed,” she noted. “The area you overlook, that is the part that I always told people is going to cause problems.”

Additionally, a substantial administrative component to the position, which oversees over 5,000 employees. “It’s a enormous management job, if you do it right,” she concluded.

Official Statement and Disputed Initiatives

When asked about questions about Høeg’s credentials and whether this assignment signifies greater collaboration among agency officials on immunizations, a press secretary responded that the “inquiries stem from flawed presumptions”.

“Her resume matches the functions of her position,” the representative explained, citing the time Høeg spent counseling the agency head on “medication safety and oversight research, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a contentious one-day therapy clearance system that apparently concerned her former heads. “By what process are these drugs being chosen for this voucher program? Who is making the decisions?” Dr. Howard questioned. “There is a lot of secrecy going on at the FDA right now.”

Broadly speaking, he said, “the FDA seems to be moving towards more relaxed oversight of all drugs, aside from vaccines.”

Public Past Work on Vaccines

Regarding immunizations, Høeg has a more established, if problematic, past, some experts said. She released a research paper using unverified volunteer-provided data to assess the rate of heart inflammation following Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccinations are more dangerous than they are.

Part of her “desired changes” for the current administration featured altering guidelines for recently developed shots and ending “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has allegedly floated the idea of excluding young men from obtaining Covid vaccines.

“She is an all-around ideologue who starts off with her beliefs and reverse-engineers to retrofit the data in a highly misleading, fraudulent fashion,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Høeg aligned with other skeptics, {like|